Virtual Event: The evolving landscape for biosimilars

Editor’s be aware: A recording of the occasion is embedded under.

Biosimilars had been anticipated to be an answer to the hovering value of prescription medicines to deal with a slew of ailments. Have they reached their potential?

Some see encouraging indicators of elevated adoption charges for these remedies, that are constructed from residing cells and almost similar to their biologic counterparts. Others concern they’re assembly resistance.

commercial

STAT’s Ed Silverman will convene a dialogue on what it can take to create a functioning biosimilar market within the U.S.

Featured Audio system:

commercial

• Madelaine A. Feldman, M.D., FACR, president, Coalition of State Rheumatology Organizations; scientific assistant professor of drugs, Tulane College Faculty of Medication
• Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice chairman, biosimilars, Cardinal Well being
• Gillian Woollett, MA, DPhil, principal analysis scientist, Avalere Well being
• Ed Silverman, Pharmalot columnist, STAT (moderator)
• Sang-Jin Pak, govt vice chairman and chief of business division, Samsung Bioepis (sponsor speaker)